Brentuximab Vedotin

證據等級: L5

預測適應症: 10 個

Brentuximab Vedotin: From Hodgkin Lymphoma to Follicular Lymphoma

Disclaimer: This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before therapeutic application.

One-Sentence Summary

Brentuximab vedotin (BV; brand name Adcetris®) is an anti-CD30 antibody-drug conjugate globally approved for classical Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL), but not currently registered with the TGA in Australia. The TxGNN model predicts it may be effective for follicular lymphoma (FL), supported by 1 actively recruiting Phase 2 clinical trial and 20 publications, primarily concentrated in CD30-positive or histologically transformed FL subgroups. The overall evidence base is at Level L3 (observational studies and case series), and patient selection by CD30 expression status is the critical gating requirement before any clinical application.

Quick Overview

Item	Content
Original Indication	Classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma (global approvals; no TGA registration in Australia)
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.89%
Evidence Level	L3
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack. Based on established pharmacological knowledge, brentuximab vedotin is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody (brentuximab) covalently linked to the potent microtubule-disrupting cytotoxin monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon binding CD30 on the surface of tumour cells, the ADC is internalised; lysosomal proteases cleave the linker, releasing MMAE intracellularly. Free MMAE disrupts tubulin polymerisation, arrests the cell cycle at G2/M, and triggers apoptosis. The global approval of BV in cHL and sALCL is founded on this CD30-selective mechanism of tumour killing.

Follicular lymphoma is typically a CD30-negative B-cell malignancy, which makes unselected FL an unlikely candidate for BV. However, a clinically important subset of FL — particularly those undergoing histological transformation towards anaplastic large cell lymphoma (ALCL) or high-grade B-cell lymphoma — can acquire robust CD30 surface expression. A published case report (PMID 32476657) documents a complete response in a patient whose Grade 1 FL transformed to CD30-positive, ALK1-negative ALCL, treated successfully with BV and high-dose methotrexate. Separately, folliculotropic mycosis fungoides — a variant of cutaneous T-cell lymphoma with marked involvement of hair follicles — has also demonstrated responsiveness to BV (PMID 41409526), supporting the concept of CD30 targeting within follicular lymphoid compartments.

The TxGNN prediction therefore reflects a biologically plausible subset hypothesis: BV is unlikely to benefit unselected FL patients, but may offer meaningful activity in the CD30-positive, transformed, or follicular T-helper cell-phenotype subpopulation. Prospective CD30 immunohistochemical screening is the essential gating criterion for any investigational use, and one actively recruiting Phase 2 trial (NCT04587687) is directly examining BV plus bendamustine in relapsed/refractory FL, providing the formal clinical framework to answer this question.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT04587687	Phase 2	Recruiting	23	BV + bendamustine for R/R follicular lymphoma. The only active FL-specific BV trial; targets CD30-positive FL. Results pending (expected completion December 2026).
NCT02623920	Phase 2	Withdrawn	0	BV + bendamustine + rituximab for R/R CD30-positive B-cell NHL including FL. Withdrawn before enrolment commenced; no data generated.
NCT04138875	Phase 2	Withdrawn	0	Risk-stratified sequential therapy with rituximab, BV, and bendamustine (RBvB) in newly diagnosed post-transplant lymphoproliferative disorders with CD20/CD30 co-expression. Withdrawn before enrolment; no data.
NCT01805037	Phase 1/2	Terminated	20	BV + rituximab as frontline for CD30+ and/or EBV+ lymphomas (including FL). Terminated early. Non-FL-specific design, but establishes the CD30 selection framework relevant to FL investigation.
NCT02594163	Phase 2	Terminated	25	Randomised R-bendamustine ± BV for R/R CD30-positive DLBCL. Terminated early; limited conclusions, but provides partial safety data for BV + bendamustine backbone used in the active FL trial.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32476657	2020	Case Report	Gulf J Oncol	Grade 1 FL transformed to CD30+ ALK1-negative ALCL achieved complete response to BV + high-dose methotrexate — the most direct published evidence of BV efficacy in the FL transformation setting
41409526	2025	Case Report	Skin Appendage Disord	Extensive follicular mucinosis (folliculotropic MF/CTCL variant) with irreversible alopecia responded to BV; supports CD30-directed targeting within follicular lymphoid tissue
35663281	2022	Review	Leuk Res Rep	Immunotherapy in indolent NHL; covers FL treatment landscape including emerging CD30-directed and immunomodulatory strategies; contextualises BV’s potential role
40758949	2025	Phase 2 Trial	Blood Adv	BV + gemcitabine (GBV) in R/R PTCL (CD30 ≥5% by IHC); primary endpoint ORR met with BV maintenance phase. Demonstrates clinically meaningful BV activity even in CD30-low lymphomas
34797505	2022	Real-World Study	Adv Ther	BV + cyclophosphamide/epirubicin/prednisone in untreated CD30+ PTCL subtypes (PTCL-TFH, ALCL, AITL) in Chinese patients; high short-term remission rates and manageable toxicity
28340875	2017	Review	Hematol Oncol Clin N Am	Angioimmunoblastic T-cell lymphoma (AITL) — a follicular T-helper (Tfh)-derived neoplasm biologically related to FL; BV highlighted as an emerging therapeutic agent in this follicular-origin disease
38306597	2024	Review	Blood	Updates BV + CHP frontline standard for CD30+ PTCLs; addresses CD30 expression threshold debate and patient selection principles directly transferable to FL subgroup design
39644004	2024	Review	Hematology ASH Educ	Comprehensive synthesis of BV incorporation into lymphoma management; discusses minimum CD30 thresholds, combination strategies, and future indications relevant to FL investigation
29023638	2018	Review	Br J Dermatol	Optimal BV regimen for CD30+ cutaneous lymphomas — addresses dosing and scheduling considerations applicable to non-classical CD30+ lymphoid malignancies
28967896	2018	Review	Bone Marrow Transplant	Post-ASCT maintenance in lymphoma; BV maintenance established for high-risk HL; also covers FL maintenance context, relevant to consolidation strategies after FL response

Australia Market Information

Brentuximab vedotin is not registered with the Therapeutic Goods Administration (TGA) and has no ARTG entries. It is not commercially available through standard Australian supply channels.

Access options for Australian clinicians:

TGA Special Access Scheme (SAS) Category B: Individual patient access for serious or life-threatening conditions where no alternative is available
Clinical Trial Enrolment: Check ANZCTR (anzctr.org.au) for any Australian sites participating in BV studies
Managed Access Programmes: Contact the Australian distributor/sponsor (Seagen/Pfizer) regarding any compassionate access pathways

Globally, Adcetris® (brentuximab vedotin) holds regulatory approval in the USA (FDA), EU (EMA), UK (MHRA), Japan (PMDA), and Taiwan (TFDA) for classical Hodgkin lymphoma, systemic ALCL, primary cutaneous ALCL, CD30+ peripheral T-cell lymphoma (BV-CHP regimen), and primary cutaneous CD30+ T-cell lymphoproliferative disorders.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted cytotoxic — Antibody-Drug Conjugate (ADC); payload MMAE is a potent synthetic auristatin-class antimitotic (microtubule inhibitor)
Myelosuppression Risk	Moderate to High — neutropenia is the most frequently reported Grade 3–4 adverse event (febrile neutropenia also documented); anaemia and thrombocytopenia occur at lower frequency
Emetogenicity Classification	Low to Moderate
Monitoring Items	Full blood count (FBC) with differential before each cycle; liver function tests (LFTs); renal function; neurological assessment for peripheral neuropathy (sensory and motor) at each visit; pregnancy test in women of childbearing potential prior to each cycle
Handling Protection	Must be prepared and administered under cytotoxic drug handling procedures — preparation in a biological safety cabinet by trained oncology pharmacy staff; appropriate personal protective equipment (gloves, gown, eye protection) required for all preparation and administration steps

Safety Considerations

No TGA-approved Australian Product Information exists. Please refer to the FDA Prescribing Information for ADCETRIS® or the EMA Summary of Product Characteristics for complete safety data. The following key safety signals are established from global post-marketing experience:

Peripheral neuropathy: Progressive cumulative sensory and motor neuropathy requiring dose delay, reduction, or permanent discontinuation — the most clinically impactful chronic toxicity
Progressive Multifocal Leukoencephalopathy (PML): JC virus reactivation leading to PML (including fatal cases) — carries a black-box warning; monitor for new or worsening neurological, cognitive, or behavioural symptoms
Pulmonary toxicity: Non-infectious pneumonitis and interstitial lung disease — hold BV and investigate any new pulmonary symptoms
Serious infections: Opportunistic infections including Pneumocystis jirovecii pneumonia and herpes zoster — PCP prophylaxis should be considered
Infusion-related reactions: Including anaphylaxis — premedication and monitoring protocols required; administration must occur in a facility equipped for anaphylaxis management
Embryo-foetal toxicity: Contraindicated in pregnancy; effective contraception required during and for 6 months after treatment for both male and female patients

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction has genuine biological plausibility for the CD30-positive or histologically transformed FL subgroup, supported by a mechanistically coherent framework (CD30-targeted MMAE delivery), a direct case report of complete response in transformed FL, and one actively recruiting Phase 2 trial. However, BV is not expected to benefit unselected, CD30-negative FL patients — the evidence base is L3, and the drug is not currently accessible in Australia through standard channels.

To proceed, the following is needed:

CD30 IHC screening protocol: Define a minimum CD30 positivity threshold (e.g., ≥1%, ≥10%, or ≥20% tumour cells) as a mandatory inclusion criterion for any FL-BV investigation — this is the single most important gating step
TGA access pathway: Clarify SAS Category B eligibility or identify Australian sites for international BV trials before initiating any patient-level discussion
Full safety documentation: Obtain the current FDA Prescribing Information and EMA SmPC to enable complete Australian formulary risk-benefit assessment and institutional pharmacy approval
Histological transformation surveillance: Develop a biopsy protocol for FL patients with clinical signs of transformation (rapid progression, elevated LDH, B symptoms) to prospectively identify the CD30+ subgroup most likely to benefit
Results of NCT04587687: Await enrolment completion and preliminary efficacy data from the only active FL-specific BV trial before committing to broader institutional investigation
Multidisciplinary consultation: Engage haematology, pharmacy, and ethics/governance prior to any SAS application given the absence of local regulatory approval and the investigational nature of this indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.